Compare Nvidia Corp (NVDA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Smith & Nephew plc — how do they compare? Nvidia Corp trades at $206.65 (market cap $4.92T), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Nvidia Corp is far larger — about 389.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| NVDA | SNN | |
|---|---|---|
Market Cap | $4.92T | $12.64B |
Sector | Technology | Health |
52-Week High | $235.75 | $38.70 |
52-Week Low | $165.17 | $28.73 |
Enterprise Value | $4.86T | $15.41B |
Dividend Yield | 0.49% | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nvidia (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $1.87 exceeding the $1.76 forecast. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97%. The stock faces resistance near $210, while support holds at $201.
Outlook remains positive due to AI-driven growth and robust profitability, but risks include peak AI spending concerns and competitive pressures. Analysts project a $325.86 price target, with 75% recommending Buy. Investors should weigh high valuation multiples against sustained earnings momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
